Pfizer Completes Acquisition of Trillium Therapeutics

On November 17, 2021, Pfizer Inc. announced the successful completion of its acquisition of Trillium Therapeutics, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. This is a great development for Trillium’s foundational technology, based on innovations originating from the lab of Dr. Jayne Danska  and collaborators at University Health Network. The novel molecule (TTI-621) targets CD47, augmenting the immune system’s ability to destroy cancer stem cells, by overcoming a “don’t eat me” signal.

Read the full story here.

Share this post